StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report report published on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of EVOK stock opened at $0.47 on Friday. Evoke Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.40. The firm has a market capitalization of $3.99 million, a PE ratio of -0.20 and a beta of 0.38. The stock’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $0.85.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The business had revenue of $1.68 million during the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- Garmin Navigates to New Highs Driven By Wearables Trend
- Want to Profit on the Downtrend? Downtrends, Explained.
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Golden Cross Stocks: Pattern, Examples and Charts
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
